Tenax Therapeutics
Tenax Therapeutics is focused on developing therapies for pulmonary hypertension, specifically PH-HFpEF, a debilitating and often fatal disease with no current approved treatments. Their mission is to address the staggering unmet medical need in this area by leveraging clinical insights and innovative drug development strategies. Their lead drug candidate, TNX-103, is an oral formulation of levosimendan, which has a well-established safety profile and potential to lower pulmonary pressures by targeting splanchnic circulation. The company is conducting Phase 3 clinical trials and is guided by a team of heart failure and lung disease experts.
Industries
Nr. of Employees
small (1-50)
Tenax Therapeutics
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517
Patents
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11969424-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11701355-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11607412-B2
View DetailsPharmaceutical compositions for subcutaneous administration of levosimendan
US-11213524-B2
View Details
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11969424-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11701355-B2
View DetailsLevosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US-11607412-B2
View DetailsPharmaceutical compositions for subcutaneous administration of levosimendan
US-11213524-B2
View DetailsProducts
Oral formulation of a K-ATP channel activator and calcium sensitizer for PH-HFpEF (clinical candidate)
An oral therapeutic candidate developed to induce splanchnic venodilation and reduce venous blood volume, with the goal of lowering pulmonary capillary wedge pressure and improving exercise capacity in patients with pulmonary hypertension from HFpEF. Development leverages prior intravenous clinical safety and hemodynamic data.
Oral formulation of a K-ATP channel activator and calcium sensitizer for PH-HFpEF (clinical candidate)
An oral therapeutic candidate developed to induce splanchnic venodilation and reduce venous blood volume, with the goal of lowering pulmonary capillary wedge pressure and improving exercise capacity in patients with pulmonary hypertension from HFpEF. Development leverages prior intravenous clinical safety and hemodynamic data.
Services
Sponsorship and operational leadership of registrational Phase 3 studies evaluating an oral therapy for pulmonary hypertension due to HFpEF, including patient enrollment, trial oversight, and open-label extension planning.
Sponsorship and operational leadership of registrational Phase 3 studies evaluating an oral therapy for pulmonary hypertension due to HFpEF, including patient enrollment, trial oversight, and open-label extension planning.
Expertise Areas
- Clinical trial management
- Translational cardiopulmonary pharmacology
- Oral formulation development
- Regulatory strategy and submissions
Key Technologies
- ATP-sensitive potassium (K-ATP) channel modulation
- Calcium sensitization pharmacology
- Oral small-molecule formulation
- Invasive hemodynamic monitoring (right-heart catheterization, PCWP)
News & Updates
LEVEL Phase 3 Trial Enrolling
A registrational Phase 3 trial for TNX-103 in PH-HFpEF is currently enrolling patients in Canada and the U.S., with topline data expected mid-2026.
LEVEL-2 Phase 3 Trial Planned
A global Phase 3 trial for TNX-103 is planned, with the first patient to be dosed by the end of 2025.
Research and Publications on PH-HFpEF and Levosimendan
Multiple scientific articles and studies have been published, highlighting the potential of levosimendan in treating PH-HFpEF and understanding its mechanisms.
A scientific statement published in the European Journal of Heart Failure discusses therapeutic discovery in pulmonary hypertension associated with left heart failure.
An article in Nature Reviews Cardiology explores the cellular and molecular mechanisms of heart failure with preserved ejection fraction.
Insights from the HELP trial on how levosimendan affects stressed blood volume in pulmonary hypertension from HFpEF.
LEVEL Phase 3 Trial Enrolling
A registrational Phase 3 trial for TNX-103 in PH-HFpEF is currently enrolling patients in Canada and the U.S., with topline data expected mid-2026.
LEVEL-2 Phase 3 Trial Planned
A global Phase 3 trial for TNX-103 is planned, with the first patient to be dosed by the end of 2025.
Research and Publications on PH-HFpEF and Levosimendan
Multiple scientific articles and studies have been published, highlighting the potential of levosimendan in treating PH-HFpEF and understanding its mechanisms.
A scientific statement published in the European Journal of Heart Failure discusses therapeutic discovery in pulmonary hypertension associated with left heart failure.
An article in Nature Reviews Cardiology explores the cellular and molecular mechanisms of heart failure with preserved ejection fraction.
Insights from the HELP trial on how levosimendan affects stressed blood volume in pulmonary hypertension from HFpEF.